Analysis of Immune Responses to HIV Vaccines
This study will evaluate a test designed to measure immune system responses to HIV and HIV vaccines.
Acquired Immunodeficiency Syndrome
|Study Design:||Observational Model: Defined Population
Time Perspective: Cross-Sectional
|Official Title:||Flow Cytometry Study of T Cell Responses to HIV Vaccines|
|Study Start Date:||April 2003|
Assays for HIV-specific human CD4 and CD8 T cell immunity are needed in order to evaluate the immune response to HIV vaccines. Such assays should be robust, reproducible, and amenable to high throughput analysis of clinical specimens. Cytokine flow cytometry (CFC) assays can reliably and specifically detect human CD4 and CD8 T cell responses to AIDS-related opportunistic infections, including those caused by cytomegalovirus, Mycobacterium tuberculosis, the Mycobacterium avium complex, cryptococcus, and human papillomavirus. The purpose of this study is to devise and evaluate a similar CFC assay for the detection and quantitation of CD4 and CD8 T cell responses against HIV.
This study will evaluate a "Gag-IFNg CFC" assay by comparing the results of this assay with results from other assays of immune phenotype and function in long-term nonprogressors, untreated patients with progressive HIV disease, and recipients of candidate HIV vaccines. The study will also examine HIV-specific immune responses in HIV infected individuals who appear to exhibit significant immune protection from HIV disease.
Participants in this study will be drawn from other studies currently underway. As a part of those studies, participants will have regular blood tests. Blood samples from those studies will be used in this study. No participants will be directly enrolled in this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00068978
|United States, California|
|Core Immunology Laboratory|
|San Francisco, California, United States, 94103|
|Principal Investigator:||Joseph M. McCune, MD, PhD||University of California at San Francisco|